NSE ScannerPharmaceuticals · Biotechnology · NSE: AKUMS · data 2026-10-30
Akums Drugs and Pharmaceuticals Limited
In plain words
Price: 12.8% below its 52-week high of ₹838.8.
Delivery: 51.9% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹4,502 cr |
| Net profit (last 12 months) | ₹292 cr |
| Sales growth, 3 years (yearly) | 6.0% |
| Profit growth, 3 years (yearly) | 39.1% |
Smart-money activity
14/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 51.5% over the last 20 sessions vs 47.6% in the 40 before (1.08x); shares delivered per day 0.56x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 1 scheme hold it, about ₹111 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 8 Aug 26Results Results board meeting +4.7% next session
- 3 Jul 26Dividend Dividend ₹1 (ex-date) -2.0% next session
- 14 May 26Results Results board meeting -4.3% next session
- 13 Feb 26Results Results board meeting +2.8% next session
- 13 Nov 25Results Results board meeting -6.4% next session
- 8 Aug 25Results Results board meeting -2.3% next session
- 26 May 25Results Results board meeting +2.0% next session
- 6 Feb 25Results Results board meeting -1.6% next session
- 9 Nov 24Results Results board meeting -10.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Akums Drugs and Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.05, which is very low.
What is Akums Drugs and Pharmaceuticals Limited's P/E ratio?
About 38.4, based on the last 12 months' earnings and a price of ₹731.7 (data 2026-10-30).
What is the 52-week high and low of Akums Drugs and Pharmaceuticals Limited?
The 52-week high is ₹838.8 and the 52-week low is ₹409.3.
Mutual funds holding Akums Drugs and Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹111 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.21% | ₹111 cr |
Similar companies
Anthem Biosciences Limited (ANTHEM) · Rubicon Research Limited (RUBICON) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH) · Haleos Labs Ltd. (HALEOSLABS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AKUMS in NSE Scanner →